A Formulation Scientist's Guide to Joint Health Supplements

Most joint health supplements are formulated backwards.

Brands start with what's cheap and available, then reverse-engineer some science to justify it. They'll throw in 15 ingredients at sub-therapeutic doses, call it "comprehensive," and hope consumers don't notice that 300mg of omega-3s won't do anything when the evidence requires 2,000mg.

Buried in the noise is genuine science. Clinical trials that separate what works from what sells. This guide breaks down the evidence, the doses, the forms that matter, and the combinations with actual synergy data.

If you're building a joint health product, start here.

The 2006 Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) is the most cited and most misunderstood study in joint health.

Study design: 1,583 patients with symptomatic knee osteoarthritis. Double-blind, placebo-controlled, 24 weeks. Five treatment arms: glucosamine alone, chondroitin alone, the combination, celecoxib (Celebrex), and placebo.

The headline result: Glucosamine and chondroitin, alone or combined, did not reduce pain effectively versus placebo in the overall population.

The buried finding: In the moderate-to-severe pain subgroup (N=354), the glucosamine + chondroitin combination showed statistically significant benefit.

The critical detail everyone ignores: GAIT used glucosamine hydrochloride, not glucosamine sulfate.

This formulation difference isn't trivial. It's everything.

Glucosamine hydrochloride and glucosamine sulfate are not interchangeable. They have different pharmacokinetics, different bioavailability, and completely different clinical evidence.

Patented crystalline glucosamine sulfate (pCGS), the Rottapharm formulation, delivers plasma levels of ~10 μmol/L. This is the concentration required to inhibit IL-1-induced expression of genes involved in joint inflammation. Glucosamine HCl does not reach these levels.

The chemical structure matters: pCGS is synthesized from chitin with glucosamine, sulfate, chloride, and sodium ions in stoichiometric ratios of 2:1:2:2. It's administered as a highly bioavailable once-daily 1,500mg dose.

Other formulations (glucosamine HCl, non-crystalline sulfate blends) have never been shown bioequivalent to pCGS. In randomized controlled trials, their effect size on pain has repeatedly been zero.

Meanwhile, pCGS has consistent positive results across multiple trials. The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) strongly recommends pCGS as first-line therapy for knee osteoarthritis and specifically discourages other glucosamine formulations.

Disease-modifying effects (pCGS only): Two 3-year trials showed that crystalline glucosamine sulfate significantly reduces joint space narrowing versus placebo.

This suggests pCGS is a disease-modifying agent in osteoarthritis. The benefit may last up to 5 years after treatment cessation, including reduction in need for total joint replacement surgery.

No other glucosamine formulation has shown these effects.

The formulation lesson: If you're using "glucosamine" without specifying crystalline sulfate in stoichiometric purity, you're formulating the ingredient that failed the GAIT trial.

Ten years after GAIT, the MOVES trial tested whether the glucosamine + chondroitin combination could match celecoxib (Celebrex) for moderate-to-severe knee osteoarthritis.

Study design: Phase IV, multicenter, non-inferiority trial in France, Germany, Poland, and Spain. Patients ≥40 years with severe pain (WOMAC pain score ≥301 on a 0-500 scale). Six-month duration.

Treatment groups:

• Chondroitin sulfate 400mg + glucosamine HCl 500mg, three times daily
• Celecoxib 200mg once daily

Results: Both groups achieved ~50% pain reduction. Clinically important and statistically significant.

Conclusion: The fixed-dose combination has comparable efficacy to celecoxib for moderate-to-severe knee osteoarthritis. This was the first study to demonstrate glucosamine + chondroitin as effective as an NSAID for knee osteoarthritis pain, without the cardiovascular and gastrointestinal risks.

Note: This trial used glucosamine HCl (not sulfate), which makes the result even more interesting. It suggests the combination may have synergistic effects that partially compensate for inferior glucosamine bioavailability.

Glucosamine's mechanisms:

• Anabolic: Stimulates glycosaminoglycan synthesis, augments type II collagen expression, provides substrate for proteoglycan production
• Anti-catabolic: Inhibits phospholipase A2, matrix metalloproteinases (MMPs), and aggrecanases, preventing cartilage degradation
• Anti-inflammatory: Decreases prostaglandin E2 synthesis, inhibits NF-κB activation, down-regulates inflammatory cytokines

Chondroitin's mechanisms:

• Anabolic: Increases synthesis of hyaluronic acid and proteoglycans, stimulates chondrocyte production
• Anti-catabolic: Reduces activity of collagenase, N-acetylglucosaminidase, aggrecanase 1 and 2, MMP-3/9/13/14, cathepsin B, and elastase
• Anti-inflammatory: Decreases NF-κB nuclear translocation, reduces pro-inflammatory cytokines, inhibits PLA2, COX-2, and NOS-2

The synergy rationale: Glucosamine inhibits phospholipase A2, MMPs, and aggrecanases. Chondroitin significantly decreases collagenolytic activity and induces proteoglycan production. The complementary mechanisms suggest synergy, though clinical evidence remains mixed (likely because most trials use inferior glucosamine forms).

UC-II (undenatured type II collagen) is one of the most misunderstood joint health ingredients. Brands see "collagen" and think they can substitute it with hydrolyzed collagen. They can't.

UC-II works at 40mg per day via oral immune tolerance. That's not a typo. Forty milligrams.

The mechanism is completely different from hydrolyzed collagen's tissue-building approach:

• UC-II reaches the small intestine intact (undenatured structure preserved)
• Interacts with gut-associated lymphatic tissue (GALT), specifically Peyer's patches
• CD103+ dendritic cells (found almost exclusively in GALT) process the undenatured collagen
• Activates T regulatory cells (Tregs) in mesenteric lymph nodes
• Tregs produce IL-10 and TGF-β (anti-inflammatory cytokines)
• Tregs travel to joints and 'teach' the immune system to be more tolerant of the body's own collagen
• Downregulate immunologic and pro-inflammatory activities at the joint

The critical requirement is epitope recognition. The three-dimensional structure of undenatured type II collagen must be preserved to trigger oral tolerance. This is why UC-II uses patented low-temperature processing from chicken sternum.

Hydrolyzed collagen is broken down into peptides. It loses structural epitopes. It cannot trigger oral tolerance. It works via a completely different mechanism (which we'll cover shortly).

Clinical evidence: A 2016 study in healthy volunteers showed that 40mg/day UC-II improved knee joint extension, lengthened the period of pain-free strenuous exertion, and alleviated joint pain from activities.

More importantly, UC-II (40mg) has been shown to be statistically significantly more effective than the glucosamine + chondroitin combination as measured by WOMAC scores (the Western Ontario and McMaster Universities Osteoarthritis Index, which evaluates pain, stiffness, and physical function in OA trials).

Three clinical studies back UC-II. Subjects experienced significantly greater range of motion versus baseline and placebo, measured by knee extension goniometry.

Patents: US 7,846,487 and 7,083,820. European patent EP 1 435 906. Manufacturing by InterHealth Nutraceuticals (now part of Lonza) in GMP-certified facilities.

The formulation lesson: You can't compare UC-II milligram-for-milligram with hydrolyzed collagen. They're fundamentally different ingredients. 40mg UC-II working via immune modulation is not "underdosed" compared to 5,000mg hydrolyzed collagen working via tissue building. They do different things.

This is the most common question in joint health formulation: hydrolyzed collagen or UC-II?

The answer: They're not alternatives. They're addressing different mechanisms. You can use both.

Hydrolyzed Collagen: The Tissue Builder

Manufacturing: Type I collagen (usually bovine or marine) undergoes heat denaturation and enzymatic hydrolysis, resulting in peptides under 6 kDa.

Absorption: High digestibility (~80% assimilation). Absorbed as di- and tri-peptides like Pro-Hyp and Gly-Pro-Hyp. Peak plasma levels occur 60-120 minutes post-ingestion.

Tissue accumulation: Labeled gelatin studies show pronounced and long-lasting accumulation in cartilage. Radioactivity in cartilage more than 2x higher following gelatin administration versus controls.

Mechanism:

• Peptides reach bloodstream
• Accumulate in cartilage tissue
• Stimulate chondrocytes
• Induce synthesis of cartilage extracellular matrix: type II collagen, proteoglycans, glycosaminoglycans
• Provide raw material for collagen synthesis in situ

Additional benefit: Glycine (abundant in collagen) inhibits pro-inflammatory cytokine release like IL-6.

Clinical evidence: A 24-week trial in athletes with activity-related joint pain showed improvement. Systematic reviews show improved joint functionality, reduced joint pain, increased collagen synthesis when combined with resistance training, and potential for injury prevention and tissue repair.

Dose: 5-10 grams daily for joint health.

Best for: Athletic recovery, tissue repair, supporting cartilage matrix synthesis.

UC-II: The Immune Modulator

We covered this above, but to reiterate the mechanism difference:

UC-II works in the gut, not the bloodstream. It's not absorbed intact into circulation. It interacts with gut-associated lymphatic tissue to activate regulatory T cells, which then modulate immune activity at the joints.

Dose: 40mg daily.

Best for: Inflammatory osteoarthritis, immune-mediated joint pain, patients who respond to immunomodulatory approaches.

Can They Be Combined?

Yes. The mechanisms are complementary, not redundant:

• UC-II: Immune modulation (downregulate inflammation at the joint)
• Hydrolyzed collagen: Tissue building (provide raw materials for cartilage repair)

A 2025 study in Scientific Reports demonstrated efficacy of combined UC-II + hydrolyzed collagen supplementation in knee osteoarthritis.

The different dose requirements (40mg vs 5-10g) make combination straightforward from a formulation perspective. No known antagonism or interaction.

Boswellia serrata extract (derived from tree resin) has one of the stronger evidence bases for joint inflammation, with rapid onset that rivals NSAIDs.

The key active: AKBA (3-O-acetyl-11-keto-β-boswellic acid). This compound is a potent inhibitor of 5-lipoxygenase (5-LOX), the key enzyme in leukotriene biosynthesis from arachidonic acid. Leukotrienes drive the cellular inflammatory cascade.

Branded extracts:

• 5-Loxin: 30% AKBA content
• Aflapin: 20% AKBA-enriched nonvolatile oil with superior oral bioavailability

Despite lower AKBA percentage, Aflapin exhibits better bioavailability, better 5-LOX inhibition, and enhanced MMP-3 inhibition compared to 5-Loxin. Delivery system matters.

Clinical evidence: The Sengupta 2008 study was a 90-day, double-blind, randomized, placebo-controlled trial with 75 osteoarthritis patients. Two doses of 5-Loxin (100mg and 250mg daily) both relieved joint pain and enhanced physical function. Negligible side effects.

Rapid onset: An Aflapin study showed significant pain reduction within 7 days of supplementation. One of the fastest-acting botanical joint ingredients.

Dual mechanism: Boswellia doesn't just reduce inflammation (5-LOX inhibition). It also has anti-catabolic effects, reducing cartilage degeneration by inhibiting MMPs.

The formulation lesson: Boswellia is particularly useful for acute flares and inflammatory presentations of osteoarthritis. It's fast-acting, has excellent safety, and works via a mechanism (5-LOX) that's distinct from COX inhibitors and other anti-inflammatories. Pair it with an ingredient that has a different mechanism (like MSM) for complementary anti-inflammatory coverage.

Methylsulfonylmethane (MSM) has modest evidence as a standalone ingredient, but it shines in combination.

MSM basics:

• Organic sulfur compound
• Generally Recognized As Safe (GRAS)
• Anti-inflammatory properties, may provide sulfur for collagen synthesis, potential antioxidant capacity
• Typical dose: 1,500-3,000mg/day
• OptiMSM (Bergstrom Nutrition) is the gold-standard distilled form

Standalone evidence: The Debbi 2011 study used 3,375mg MSM daily for 12 weeks in knee osteoarthritis patients. WOMAC pain decreased 21% (not statistically significant). VAS pain scale decreased 5.5% (statistically significant, p<0.05). Modest benefit.

Combination evidence: A randomized trial compared MSM + boswellic acids versus glucosamine sulfate over 6 months. The MSM + boswellia combination showed improvements in pain scores and enhanced joint function, with a tendency toward better values at 6 months versus glucosamine alone.

The formulation lesson: MSM's modest standalone evidence becomes more compelling when combined with Boswellia. The two ingredients attack inflammation via different pathways, and the clinical trial data supports the combination versus glucosamine alone.

Omega-3 fatty acids (EPA and DHA) are ubiquitous in joint health formulations, but most brands underdose them. Here's what the evidence says about omega-3 for joint pain relief and why you need at least 2 grams daily for anti-inflammatory effect.

Mechanism: Omega-3s have direct anti-inflammatory effects (blocking cytokines and prostaglandins, replacing arachidonic acid in cell membranes) and indirect effects via conversion to specialized pro-resolving mediators (SPMs): resolvins, protectins, and maresins.

These aren't just anti-inflammatory. They actively promote the resolution phase of inflammation. EPA gives rise to eicosanoid mediators that are far less inflammatory than those produced from omega-6 arachidonic acid.

Evidence-based range: 2-3g/day EPA+DHA combined. For rheumatoid arthritis specifically, some studies use >2.6g/day.

RA versus OA evidence:

Omega-3s have been tested in 20 clinical trials for rheumatoid arthritis. 16 showed significant improvements in joint pain, stiffness, and swelling. Higher doses (>2.6g/day) lowered inflammatory biomarkers like CRP and ESR.

For osteoarthritis, only 4 trials exist, and 3 showed improvements in at least one clinical parameter. The evidence for OA remains inconclusive.

Why the difference? Rheumatoid arthritis is inflammation-driven. Omega-3s directly target inflammatory pathways, so they're highly effective. Osteoarthritis is primarily mechanical wear-and-tear; inflammation is secondary. Omega-3s are less effective when inflammation isn't the primary driver.

Combination synergy: Network meta-analysis found that glucosamine + omega-3 ranked highest for pain reduction in knee osteoarthritis and was the only effective intervention for reducing long-term pain. Safety was excellent. Glucosamine + omega-3 resulted in the lowest odds of adverse events.

The formulation lesson: If you're including omega-3s in a joint health formula, dose them properly (≥2g EPA+DHA). Consider pairing with glucosamine for synergy. And manage expectations: omega-3s work better for inflammatory joint conditions (RA) than degenerative ones (OA), though the combination data is promising.

Oral hyaluronic acid (HA) is a controversial ingredient. The central question: How does a molecule with molecular weight ~900,000 Da get absorbed through the GI tract?

Conventional wisdom says it doesn't. And that might be fine.

Proposed mechanisms:

Mechanism 1: N-acetyl glucosamine release. HA breaks down in the GI tract and releases N-acetyl glucosamine, which may improve osteoarthritis symptoms similar to glucosamine (chondroprotective and anti-inflammatory).

Mechanism 2: Gut microbiome interaction. HA may work via microbiome modulation rather than direct joint delivery. This is an emerging research area.

Clinical evidence: The Tashiro 2012 study was a double-blind, placebo-controlled, 12-month trial with 60 osteoarthritic patients (Kellgren-Lawrence grade 2 or 3). HA group received 200mg HA once daily (molecular weight ~900,000 Da, 97% purity).

Symptoms improved in both HA and placebo groups. Improvement tended to be more obvious in the HA group. Significant benefit in subgroup: Patients aged ≤70 years showed greater improvement.

Important finding: Oral HA combined with quadriceps strengthening exercise may improve symptoms in patients ≤70 years.

Evidence-based dose: 80-200mg/day (most studies use 200mg). Higher doses not shown to provide additional benefit.

The formulation lesson: Oral HA has modest effects that may be age-dependent (better in younger patients ≤70) and work best combined with exercise. The mechanism is unclear (possibly indirect via glucosamine-like breakdown products or microbiome effects). It's not a primary ingredient, but it has some positive clinical data and a clean safety profile.

Curcumin blocks NF-κB activation, inhibits pro-inflammatory cytokines and enzymes, and reduces joint pain and swelling in most clinical trials. The problem: systemic bioavailability is poor.

Curcumin concentrations are extremely low or nonexistent in serum and tissues even after 500-8,000mg doses. However, curcumin metabolites may be responsible for anti-inflammatory properties.

Clinical evidence for OA: Most studies show curcumin significantly reduced pain and improved function versus placebo, assessed by VAS and WOMAC scores.

The formulation lesson: Standard curcumin is essentially unabsorbable. If you're formulating with curcumin, you must use enhanced bioavailability technology: piperine (cheapest, 2000% increase), phospholipids, nanoparticles, or liposomal forms. Without it, you're including an ingredient that won't reach therapeutic levels.

NEM (Eggshell Membrane): Fast-Acting Stiffness Relief

Natural eggshell membrane from chicken eggs contains glycosaminoglycans, proteins, glucosamine (up to 1%), chondroitin sulfate (up to 1%), hyaluronic acid (up to 2%), and collagen type I (up to 5%).

Dose: 500mg/day.

Speed: The OPTION trial (8-week RCT) showed rapid responses at 10 days.

Network meta-analysis ranked NEM as the most effective intervention for stiffness in knee OA.

The advantage: Fast-acting (7-10 days) compared to most joint supplements (4-12 weeks). Excellent for combination formulas where you want early wins while slower-acting ingredients (glucosamine, UC-II) build efficacy.

Green-Lipped Mussel Extract: The Unique ETA Omega-3

Perna canaliculus, endemic to New Zealand, contains a rare omega-3: eicosatetraenoic acid (ETA, 20:4 omega-3). ETA is found almost nowhere else and has exceptional anti-inflammatory benefits.

Mechanism: Inhibits both cyclooxygenase (COX) and lipoxygenase (LOX) cascades (dual COX/LOX inhibition, similar to prescription drugs but from a natural source). Also provides EPA, DHA, glycosaminoglycans, and proteins.

Clinical evidence: Meta-analysis shows green-lipped mussel extracts (lipid extract or whole powder) provide moderate and clinically significant treatment effects on VAS pain scores. Network meta-analysis found green-lipped mussel extract had clinically important effects on pain at medium term (versus short term only for most supplements).

Forms: Lipid extract (concentrated omega-3s including ETA) or whole powder (includes proteins and GAGs).

SAMe: Prescription in Europe, OTC in the US

S-adenosylmethionine (SAMe) is a naturally occurring chemical not found in foods. It acts as an analgesic and anti-inflammatory, may stimulate cartilage growth, and affects neurotransmitters like serotonin to reduce pain perception.

Regulatory status: Over-the-counter supplement in the USA; prescription medication in some European countries (Italy, Spain).

Clinical evidence: Many studies show SAMe provides similar pain relief and joint function improvement as NSAIDs with fewer side effects. Participants taking SAMe were 58% less likely to experience side effects than those on NSAIDs. A double-blind cross-over trial showed SAMe had comparable efficacy to celecoxib for osteoarthritis symptoms.

Caveat: Cochrane review found mixed results. Some measures showed no difference between SAMe and placebo.

Vitamin D: Only for the Deficient

Vitamin D regulates calcium absorption, prevents osteoporosis, regulates autoimmune function, fights inflammation, and impacts bone quality.

Clinical evidence: Patients with knee OA and vitamin D deficiency showed improvements with supplementation (improved muscle strength, better knee function, reduced pain).

Important caveat: Subset analyses indicate vitamin D supplementation may alleviate joint pain in OA patients with low vitamin D status (<50 nmol/L). Effect appears dependent on baseline status. May be beneficial for pain symptoms but might not contribute to radiographic changes.

Dosing: Clinical studies show 4,000 IU/day for 3 months produced significant pain reduction and increased functionality. Long-term safety established at 50,000 IU per month in a 2-year OA study.

The formulation lesson: Vitamin D is worth including if you're targeting a population likely to be deficient (elderly, limited sun exposure, darker skin in northern latitudes). It's not a universal joint health ingredient. It works for the deficient.

Most combination formulas are built on hope, not data. Here's what the clinical evidence says about synergy:

Other evidence-based combinations:

MSM + Boswellia: Randomized trial showed combination had improvements in pain scores and enhanced joint function versus glucosamine sulfate alone. Mechanism complementarity: MSM (anti-inflammatory, sulfur donor) + Boswellia (5-LOX inhibition).

UC-II + Hydrolyzed Collagen: 2025 study in Scientific Reports showed efficacy. Rationale: immune modulation (UC-II) + tissue building (hydrolyzed collagen) address different pathways.

Curcumin + Piperine: Not joint-specific, but piperine increases curcumin bioavailability by 2000%. This is a co-delivery system, not a therapeutic synergy, but functionally critical.

Medium-term effects: Only green-lipped mussel extract and UC-II had clinically important effects on pain at medium term, according to network meta-analysis.

The formulation lesson: Don't throw 15 ingredients together and call it synergy. Use evidence-based combinations with complementary mechanisms: glucosamine + omega-3 (cartilage + anti-inflammatory), UC-II + hydrolyzed collagen (immune + tissue), MSM + Boswellia (different anti-inflammatory pathways).

Most joint health formulas treat all joint pain the same. That's a mistake.

Rheumatoid arthritis (RA): Autoimmune inflammation. Immune system attacks synovial membrane. Systemic inflammatory disease affecting multiple joints symmetrically. Elevated CRP and ESR.

Osteoarthritis (OA): Mechanical wear-and-tear, cartilage degradation. "Degenerative joint disease." Inflammation secondary to tissue damage (not primary cause). Affects weight-bearing joints, often asymmetric. Lower systemic inflammation.

The formulation lesson: A "joint health" product designed for RA should emphasize high-dose omega-3s, curcumin, and vitamin D. A product for OA should emphasize glucosamine sulfate, UC-II, hydrolyzed collagen, and SAMe. Generic formulas that ignore disease mechanism are suboptimal for both.

Most research focuses on knee osteoarthritis. Hip and hand OA are understudied.

Evidence concentration:

• Knee OA: Strong evidence for NEM (stiffness), Aflapin (pain), glucosamine + omega-3 (long-term pain)
• Hip OA: Limited data. ACR recommends against glucosamine/chondroitin for hip OA. ASU (Avocado-Soybean Unsaponifiables) showed modest structural benefit in the ERADIAS study (20% fewer progressors but no clinical symptom benefit)
• Hand OA: Very limited. ACR recommends against glucosamine. Chondroitin evidence mixed

The formulation lesson: If you're targeting knee OA, you have strong evidence for multiple ingredients. If you're targeting hip or hand OA, acknowledge the evidence limitations and focus on ingredients with at least some data (ASU for hip, curcumin as a general anti-inflammatory).

Most joint health products fail at the formulation stage. Whether you're selecting joint health ingredients for a new product or auditing an existing formula, here's how evidence-based formulators approach it:

1. Specify the Right Forms

• Glucosamine: Patented crystalline glucosamine sulfate (pCGS, Rottapharm formulation), not glucosamine HCl. Follow ESCEO guidelines.
• Boswellia: AKBA-standardized extract (minimum 10-20%). Prefer Aflapin (better bioavailability) or 5-Loxin (higher AKBA content).
• Curcumin: Include bioavailability enhancement. Piperine (cheapest, 2000% increase), BCM-95, Theracurmin, or liposomal.
• Omega-3s: Specify EPA+DHA content, not just "fish oil." Test oxidation (TOTOX value). Aim for ≥2g EPA+DHA for anti-inflammatory effect.
• Chondroitin: Precision fermentation forms have improved absorption versus animal-derived.

2. Dose According to Clinical Evidence

• UC-II: 40mg (not 400mg, not 4g). It's an immune modulator, not a tissue builder.
• Glucosamine sulfate: 1,500mg once daily (crystalline form). Don't split dosing.
• Chondroitin sulfate: 1,200mg daily.
• Omega-3s: ≥2g EPA+DHA combined.
• Boswellia: 100-250mg (AKBA-standardized).
• MSM: 1,500-3,000mg.
• Hydrolyzed collagen: 5-10g if you're using it for tissue building (not comparable to UC-II).
• NEM: 500mg for fast-acting stiffness relief.

3. Combine Based on Mechanism Complementarity, Not Redundancy

4. Match Ingredients to Condition and Patient Demographics

• For RA: Emphasize omega-3s (≥2.6g), curcumin, vitamin D, Boswellia
• For OA: Emphasize crystalline glucosamine sulfate, UC-II, hydrolyzed collagen, SAMe
• For knee OA specifically: Strongest evidence base (can use full arsenal)
• For hip OA: Limited evidence (consider ASU, acknowledge data gaps)
• For patients ≤70 years: Oral HA may provide benefit (age-dependent response)
• For vitamin D-deficient populations: Include vitamin D (4,000 IU range)

5. Build in Fast-Acting + Long-Acting Ingredients

This approach provides early wins (patient compliance) while building long-term efficacy.

6. Enhance Bioavailability Where It Matters

• Curcumin: Piperine, BCM-95, Theracurmin, or liposomal (pick one)
• Boswellia: Aflapin has better bioavailability than 5-Loxin despite lower AKBA percentage
• Chondroitin: Precision fermentation for improved absorption
• Fat-soluble vitamins (D, E, K): Formulate with or recommend taking with healthy fats
• Minerals: Use chelated forms over inorganic salts

7. Use Branded, Clinically Validated Ingredients

• UC-II® (Lonza): Patented, clinical trials, 40mg dose
• OptiMSM® (Bergstrom Nutrition): Distilled, gold-standard
• 5-Loxin® or Aflapin®: AKBA-standardized Boswellia
• NEM®: Standardized eggshell membrane, 500mg
• Piascledine®: Only ASU product with robust RCT data

Branded ingredients cost more, but they come with clinical validation and quality control. Generic "glucosamine" or "Boswellia extract" without specifications is formulation theater.

8. Don't Overpromise on Timeframes

Brands that promise "instant relief" from glucosamine are lying. Brands that don't communicate different timeframes for different ingredients lose customers who quit at 2 weeks.